Table 1. Baseline characterization of patients enrolled within the ASLI study (n=47).
| Age (years) mean±SD | 76±8 |
| Female/male (%) | 61/39 |
| Previous bevacizumab treatment, number (%) | |
| 3 | 15 (32%) |
| 4 | 4 (8%) |
| 5 | 3 (6%) |
| 6 | 9 (19%) |
| 7 | 7 (15%) |
| 8 | 1 (2%) |
| 9 | 8 (17%) |
| Vitreoretinal interface, number (%) | |
| Attached vitreous | 18 (38%) |
| PVD | 15 (32%) |
| ERM | 1 (2%) |
| VMT | 1 (2%) |
| Drusen type, number (%) | |
| Typical AMD | 36 (77%) |
| Cuticular | 3 (6%) |
| Subretinal drosenoid | 3 (6%) |
| Retinal fluid, number (%) | |
| SRF | 33 (70%) |
| IRF | 18 (38%) |
| PED | 21 (45%) |
Abbreviations: AMD, age-related macular degeneration; ERM, epiretinal membrane; IRF, intraretinal fluid; PED, pigment epithelium detachment; PVD, posterior vitreous detachment; SRF, subretinal fluid; VMT, vitreomacular traction.